Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $1.5 million.

  • Aligos Therapeutics' Share-based Compensation fell 2819.38% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 4327.97%. This contributed to the annual value of $8.5 million for FY2024, which is 3319.63% down from last year.
  • Per Aligos Therapeutics' latest filing, its Share-based Compensation stood at $1.5 million for Q3 2025, which was down 2819.38% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Aligos Therapeutics' Share-based Compensation registered a high of $4.0 million during Q2 2022, and its lowest value of $959000.0 during Q1 2025.
  • Moreover, its 5-year median value for Share-based Compensation was $3.2 million (2023), whereas its average is $2.8 million.
  • In the last 5 years, Aligos Therapeutics' Share-based Compensation skyrocketed by 3737.3% in 2022 and then tumbled by 6378.4% in 2025.
  • Aligos Therapeutics' Share-based Compensation (Quarter) stood at $3.7 million in 2021, then fell by 6.44% to $3.4 million in 2022, then dropped by 24.39% to $2.6 million in 2023, then tumbled by 33.99% to $1.7 million in 2024, then decreased by 13.96% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.2 million for Q2 2025, and $959000.0 during Q1 2025.